Genomic landscape of pancreatic neuroendocrine tumors

Table 1 Clinical and histopathological features of the patients included in the study group

Case No.	Sex	Age	Diagnosis (WHO 2010)	Mitotic score	Ki67	Tumor size (cm)	TNM (UICC)
P01	F	45	NET G1	< 1	< 1%	3.5	pT2, pN0(0/10), pM1, L0, V0, pN0
P02	F	77	NET G2	2	3%	14	pT3, pN1, pMx, L1, V1, pN0
P03	M	45	NET G1	< 1	1%	2.3	pT2, pNx, pMx, L0, V0, pN0
P04	M	57	NET G1	1	10%	3.8	pT3, pN0, pM1, L1, V0, pN0, G1
P05	M	50	NET G1	< 1	0.4%	1.1	pT1, pNx, pMx, L0, V0, pN0, G1
P06	M	61	NET G1	< 1	2.6%	5	pT3, pN0 (0/5), pMx, L0, V0, pN0, G1
P07	F	77	NET G3	25	35%	10	pT3, pN0, pMx, L1, V0, pN0
P08	M	58	NET G1	< 1	< 1%	0.3	pT1, pNx, pMx, L0, V0, pN0, G1
P09	M	33	NET G2	2	4.7%	2.8	pT2, pN1 (2/26), pMx, L1, V0, pN0, G2
P10	M	50	NET G2	5	12.4%	> 20	pT4, pNx, pM1, L1, V1, pN1, G2
P11	F	16	NET G2	3	16.1%	5	pT3, pN1 (19/68), pM1, L1, V0, pN1, G2
P12	F	33	NET G2	2	1.2%	2	pT1, pN0, pMx, L0, V0, pN0, G2
P13	F	38	NET G2	2	7%	5.5	pT3, pN1 (2/15), pM1, L1, V0, pN1, G2
P14	M	58	NET G2	10	6.5%	4.5	pT3, pN1(8/23), pMx, L0, V1, pN1, G2
P15	M	72	NET G1	< 1	1.5%	1.5	pT1, pNx, pM1, L0, V0, pN0, G1
P16	F	60	NET G1	< 1	0.5%	1.1	pT1, pN0 (0/6), pMx, L0, V0, pN0, G1
P17	F	77	NET G1	< 1	0.8%	1	pT1, pNx, pMx, L0, V0, pN0 ,G1
P18	F	49	NET G1	< 1	1.4%	2.7	pT2, pN0 (0/5), pMx, L1, V0, pN0, G1
P19	F	52	NET G2	5	14.6%	4	pT3, pN0, pM1, L1, V1, pN1, G2
P20	F	46	NET G1	1	6%	9.5	pT2, pN0(0/9), pMx,L1,V1,pN0, G1
P21	M	55	NET G1	< 1	2.9%	3	pT3, pN1 /1/15), pM1, V0, L1, pN0, G1
P22	M	31	NET G1	1	2.2%	0.9	pT1, pN0 (0/5), pMx, L0, V0, pN0, G1
P23	M	56	NET G1	< 1	1%	0.4	pT1, pN0, pM0, L0, V0, pN0, G1
P24	M	42	NET G1	0	0.3%	0.2	pT1(m), pN0 (0/3), pMx, L0,V0, pN0, G1
P25	M	68	NET G1	< 1	1.2%	2.5	pT2, pNx, pMx, L0, V0, pN0, G1
P26	F	33	NET G1	< 1	1.3%	2	pT1, pNx, pMx, L0, V0, pN0, G1
P27	F	50	NET G1	< 1	2%	2.7	pT2, pNx, pMx, L0, V0, pN0, G1
P28	M	59	NET G1	1	1.2%	3.5	pT2, pN1(1/20), pMx, L1, V1, pN0, G1
P29	F	57	NET G1	< 1	1.5%	0.8	pT1, pN0, pMx, L0, V0, pN1, G1
P30	F	59	NET G1	< 1	1%	2.1	pT2, pN0 (0/1), pMx L0, V0, pN0, G1
P31	M	86	NET G1	< 1	1%	0.7	pT1(m), pNx, pMx, L0, V0, pN0, G1
P32	F	81	NET G1	< 1	0%	0.8	pT1, pN0 (0/14), pMx, L0, V0, pN0, G1
P33	F	51	NET G1	1	0.5%	9	pT2, pN1 (7/26), pMx, L1, V0, pN0, G1
P34	F	45	NET G1	1	0.9%	2	pT1(m), pN0, pM1, L0, V0, pN0, G1
P35	F	41	NET G1	< 1	< 1%	2	pT1, pNx, pMx, L0, V0, pN0, G1
P36	F	40	NET G1	< 1	0.8%	0.6	pT1, pN0 (0/21), pM0, L0, V0, pN0, G1
P37	M	70	NET G1	< 1	1%	0.5	pT1, pN0 (0/12), pM0, L0, V0, pN0

F: Female; M: Male; NET: Neuroendocrine tumor; UICC: International Union Against Cancer.

Table 2 Primary pancreatic tumors included in the study group

Case No.	Primary tumor	Localization	Mitotic score	Ki67	Number of CNAs in primary tumor	Number of CNAs in metastases
M_P8.1	P08	LN	< 1	1%	0	7
M_P8.2	P08	LN	2	4%	0	4
M_P10.1	P10	LN	2	7%	22	5
M_P10.2	P10	Peritoneal	3	21%	19	7
M_P12.1	P12	LN	2	4%	28	4
M_P12.2	P12	Liver	< 1	< 1%	28	0
M_P13.1	P13	Liver	5	15%	1	37
M_P32.1	P32	LN	< 1	1%	56	70
M_P32.2	P32	Peritoneal	< 1	1%	59	14
M_P33.1	P33	Peritoneal	< 1	1%	6	2
M_P36.1	P36	Liver	8	20%	11	3

CNA: Copy number alterations; LN: Lymph node.

Table 3 Comparison of copy number alterations by array-based comparative genomic hybridization in recurrent regions in primary tumors and metastases n (%)

Recurrent region	Primary tumor	Metastases	All tumors
n	37	11	48
Gains
01q21.3-q22	4 (10.8)	1 (9.1)	5 (10.4)
03q24	4 (10.8)	0 (0)	4 (8.3)
06p22.2-p22.1	9 (24.3)	4 (36.4)	13 (27.1)
07p21.3-p21.2	6 (16.2)	3 (27.3)	9 (18.8)
07q21.11-q21.12	2 (5.4)	3 (27.3)	5 (10.4)
08q24.3	4 (10.8)	1 (9.1)	5 (10.4)
09q34.11	6 (16.2)	3 (27.3)	9 (18.8)
11q13.1-q13.2	2 (5.4)	2 (18.2)	4 (8.3)
16p11.2	2 (5.4)	3 (27.3)	5 (10.4)
16q22.1	5 (13.5)	1 (9.1)	6 (12.5)
17p13.1	7 (18.9)	3 (27.3)	10 (20.8)
18q12.1	5 (13.5)	0 (0)	5 (10.4)
19p13.3	4 (10.8)	0 (0)	4 (8.3)
22q13.33	1 (2.7)	2 (18.2)	3 (6.3)
Losses
08q24.3	3 (8.1)	0 (0)	3 (6.3)
11q13.1-q13.2	2 (5.4)	0 (0)	2 (4.2)
16p11.2	2 (5.4)	0 (0)	2 (4.2)
16q22.1	1 (2.7)	0 (0)	1 (2.1)
17p13.1	1 (2.7)	0 (0)	1 (2.1)
22q13.33	0 (0)	1 (9.1)	1 (2.1)